Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1-Infected Patients
Authors:
Open Access
- 1 January 2011
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (1) , 122-127
Abstract
Background. To determine the rate of seroconversion after 2 doses of a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in human immunodeficiency virus type 1 (HIV-1)–infected patients (ClinicalTrials.gov NCT01017172). Methods. Diagnostic study of adult HIV-1–infected patients scheduled for H1N1 influenza A vaccination. Blood samples where taken before and 21 days after the first dose and 21 days after the second dose of the vaccine. Antibody (AB) titers were determined by hemagglutination inhibition assay. Seroconversion was defined by either an AB titer ≤1:10 before and ≥1:40 after or ≥1:10 before and a ≥4-fold increase in AB titer 21 days after vaccination. Results. One hundred thirty-five patients received 2 doses of the H1N1 vaccine and were analyzed. The rate of seroconversion was 68.2% (95% confidence interval, 59.6–75.9) after the first dose and 91.9% (95% confidence interval, 85.9–95.9) after the second dose. Patients who did not seroconvert had a lower mean nadir CD4 cell count (±standard deviation; 81 ± 99 vs 190 ± 148 cells/μL; P = .006), had a longer duration of HIV infection (±standard deviation; 13.1 ± 5.9 vs 8.8 ± 6.8 years; P = .04), and were more likely to have an AB titer ≥1:40 before vaccination (4% vs 55%; P < .001) when compared with patients with seroconversion. No other differences were found between the 2 groups, including AIDS status, highly active antiretroviral therapy status, HIV RNA - polymerase chain reaction load Conclusion. Among HIV-infected patients, the rate of seroconversion after the first dose of an adjuvanted H1N1 influenza A vaccine was 68% and increased to 92% after a second doses.Keywords
This publication has 19 references indexed in Scilit:
- Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patientsAIDS, 2010
- Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?Medical Microbiology and Immunology, 2010
- A Novel Influenza A (H1N1) Vaccine in Various Age GroupsNew England Journal of Medicine, 2009
- Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responsesThe Lancet Infectious Diseases, 2009
- Humoral Response to Influenza Vaccination in HIV-Infected PatientsClinical Drug Investigation, 1999
- Activation of virus replication after vaccination of HIV-1-infected individuals.Journal of Experimental Medicine, 1995
- The Influence of Human Immunodeficiency Virus (HIV) Infection on Antibody Responses to Influenza VaccinesAnnals of Internal Medicine, 1988
- Characterization of the Immune Response to Trivalent Influenza Vaccine in Elderly MenJournal of the American Geriatrics Society, 1987
- The Immune Response to Influenza Infection1986
- IMMUNITY TO INFLUENZA IN MANAnnual Review of Microbiology, 1983